EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

mRNA-based HIV-1 vaccines

Shamim Ahmed, Alon Herschhorn iD

Clinical Microbiology Reviews · 12.09.2024 · 37 (3)

DOI: 10.1128/cmr.00041-24 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Microbiology Reviews, erschienen am 12.09.2024. Verfasst von Shamim Ahmed und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: HIV-1, AIDS Vaccines, HIV Infections. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The success of the Severe Acute Respiratory Syndrome Coronavirus 2 mRNA vaccines to lessen/prevent severe COVID-19 opened new opportunities to develop RNA vaccines to fight other infectious agents. HIV-1 is a lentivirus that integrates into the host cell genome and persists for the lifetime of infected cells. Multiple mechanisms of immune evasion have posed significant obstacles to the development of an effective HIV-1 vaccine over the last four decades since the identification of HIV-1. Recently, attempts to address some of these challenges have led to multiple studies that manufactured, optimized, and tested, in different animal models, mRNA-based HIV-1 vaccines. Several clinical trials have also been initiated or are planned to start soon. Here, we review the current strategies applied to HIV-1 mRNA vaccines, discuss different targeting approaches, summarize the latest findings, and offer insights into the challenges and future of HIV-1 mRNA vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1AIDS VaccinesHIV InfectionsHumansAnimalsmRNA VaccinesRNA, MessengerVaccines, SyntheticSARS-CoV-2COVID-19

Stichwörter der Autor:innen

HIV-1envelope glycoproteinsmRNA vaccines

Substanzen

AIDS VaccinesmRNA VaccinesRNA, MessengerVaccines, Synthetic

Autor:innen und Institutionen

  • Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
  • Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, USA.
  • Center for Genome Engineering, Medical School, University of Minnesota, Minneapolis, Minnesota, USA.
  • Institute for Engineering in Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
  • Microbiology, Immunology, and Cancer Biology Graduate Program, University of Minnesota, Minneapolis, Minnesota, USA.
  • The College of Veterinary Medicine Graduate Program, University of Minnesota, Minneapolis, Minnesota, USA.

ORCID-Profile: Alon Herschhorn

Förderung

  • NIAID NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)

Zitieren

APA

Ahmed, S., & Herschhorn, A. (2024). mRNA-based HIV-1 vaccines. Clinical Microbiology Reviews, 37(3). https://doi.org/10.1128/cmr.00041-24

Vancouver

Ahmed S, Herschhorn A. mRNA-based HIV-1 vaccines. Clinical Microbiology Reviews. 2024;37(3). doi:10.1128/cmr.00041-24

BibTeX
@article{Ahmed2024,
  author = {Ahmed, Shamim and Herschhorn, Alon},
  title = {mRNA-based HIV-1 vaccines},
  journal = {Clinical Microbiology Reviews},
  year = {2024},
  volume = {37},
  number = {3},
  doi = {10.1128/cmr.00041-24}
}
Kostenlos starten →